Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | LCK | P06239 | 4/20 | 0.61 |
| ▸ | JAK3 | P52333 | 4/20 | 0.61 |
| ▸ | ITK | Q08881 | 4/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | PRKDC | P78527 | 4/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702425 | 0.91 | BTK (0.63) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701650 | 0.91 | PIK3CD (0.58) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701889 | 0.91 | BTK (0.62) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16712869 | 0.90 | BTK (0.61) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701436 | 0.89 | BTK (0.77) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701967 | 0.87 | PIK3CD (0.66) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16702033 | 0.87 | BTK (0.62) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701614 | 0.87 | BTK (0.64) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701500 | 0.87 | PIK3CD (0.65) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL16701964 | 0.86 | FGFR2 (0.59) | BTKEGFRLCKJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | claimed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | BTK 1/4885EGFR 828/4885LCK 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.